Labs in Court: Two EKRA-Related Cases and Some Usual Suspects
Recent enforcement actions involved usual targets such as COVID-19, genetic, and urine drug testing, but EKRA also made an appearance
Recent enforcement actions involved usual targets such as COVID-19, genetic, and urine drug testing, but EKRA also made an appearance
This Lab Institute presentation shares recent enforcement trends and how labs can avoid compliance risks related to these issues.
COVID-19-related schemes dominated recent enforcement efforts, which include a national healthcare fraud enforcement action
Examining what led to record low BB/TM ABPath certification examination pass rates in 2022
Examining DOJ and OIG investigations of labs and their owners: Recent cases show continued focus on the usual enforcement targets.